A phase I trial single-ascending dose of SAGE-324 for essential tremor
Phase of Trial: Phase I
Latest Information Update: 07 Jan 2019
Price : $35 *
At a glance
- Drugs SAGE-324 (Primary)
- Indications Epilepsy; Essential tremor; Parkinson's disease
- Focus Adverse reactions
- 07 Jan 2019 According to a Sage Therapeutics media release, the company recently completed this study. Topline results from this SAD study is expected in 1H 2019.
- 07 Jan 2019 Status changed from planning to completed, according to a Sage Therapeutics media release
- 07 Aug 2018 According to a Sage Therapeutics media release, top-line results from the study are expected in 4Q 2018.